Text Size
43 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Urogenital Neoplasms"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: hydroxychloroquine
2 Recruiting Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: therapeutic allogeneic lymphocytes;   Drug: sunitinib malate
3 Recruiting Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy;   Drug: docetaxel
4 Recruiting Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
Conditions: Endometrial Cancer;   Fatigue;   Neurotoxicity
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Radiation: brachytherapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy
5 Recruiting Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: flutamide;   Radiation: radiation therapy
6 Recruiting Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
Conditions: Adenocarcinoma of the Bladder;   Recurrent Bladder Cancer;   Squamous Cell Carcinoma of the Bladder;   Stage 0 Bladder Cancer;   Stage I Bladder Cancer;   Stage II Bladder Cancer;   Stage III Bladder Cancer;   Transitional Cell Carcinoma of the Bladder
Interventions: Procedure: conventional surgery;   Biological: recombinant fowlpox-TRICOM vaccine
7 Recruiting Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Conditions: Brain and Central Nervous System Tumors;   Kidney Cancer;   Sarcoma
Interventions: Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate
8 Recruiting Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Conditions: Kidney Cancer;   Nonneoplastic Condition
Interventions: Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
9 Recruiting MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Kidney Cancer;   Leukemia;   Liver Cancer;   Neuroblastoma;   Sarcoma
Interventions: Drug: alisertib;   Other: laboratory biomarker analysis;   Other: pharmacological study
10 Recruiting Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms Tumor
Condition: Kidney Cancer
Interventions: Biological: dactinomycin;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Procedure: therapeutic conventional surgery;   Radiation: external beam radiation therapy
11 Recruiting Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor
Conditions: Kidney Cancer;   Metastatic Cancer
Interventions: Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
12 Unknown † Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Condition: Kidney Cancer
Interventions: Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
13 Recruiting Study of Kidney Tumors in Young Patients
Conditions: Kidney Cancer;   Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
14 Recruiting Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
15 Recruiting 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Condition: Prostate Cancer
Interventions: Drug: Abiraterone acetate;   Drug: Abiraterone acetate plus degarelix;   Drug: Degarelix
16 Recruiting Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Condition: Prostate Cancer
Interventions: Drug: Androgen Deprivation Therapy;   Drug: bicalutamide;   Drug: bevacizumab
17 Recruiting Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor-negative Breast Cancer;   Fallopian Tube Cancer;   HER2-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer (BRCA1, BRCA2);   Male Breast Cancer;   Primary Peritoneal Cavity Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Prostate Cancer;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
18 Not yet recruiting Phase II Study of ABT-263/Abiraterone or ABT-263/Abiraterone/Hydroxychloroquine in Prostrate Cancer
Condition: Castrate Refractory Prostate Cancer (CRPC)
Interventions: Drug: Abiraterone;   Drug: ABT-263;   Drug: Hydroxychloroquine
19 Unknown † AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Malignant Tumor of Peritoneum
Interventions: Biological: rilotumumab;   Other: laboratory biomarker analysis
20 Recruiting S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Conditions: Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma;   Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years